These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28852467)

  • 1. Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma.
    Colia V; Fiore M; Provenzano S; Fumagalli E; Bertulli R; Morosi C; Dei Tos AP; Barisella M; Gronchi A; Casali PG; Sanfilippo R
    Clin Sarcoma Res; 2017; 7():16. PubMed ID: 28852467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to chemotherapy of solitary fibrous tumour: a retrospective study.
    Stacchiotti S; Libertini M; Negri T; Palassini E; Gronchi A; Fatigoni S; Poletti P; Vincenzi B; Dei Tos AP; Mariani L; Pilotti S; Casali PG
    Eur J Cancer; 2013 Jul; 49(10):2376-83. PubMed ID: 23566418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma.
    Colia V; Fumagalli E; Provenzano S; Bertulli R; Stacchiotti S; Morosi C; Collini P; Gronchi A; Casali PG; Sanfilippo R
    Sarcoma; 2017; 2017():3739159. PubMed ID: 28947876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma.
    Sanfilippo R; Bertulli R; Marrari A; Fumagalli E; Pilotti S; Morosi C; Messina A; Dei Tos AP; Gronchi A; Casali PG
    Clin Sarcoma Res; 2014; 4(1):16. PubMed ID: 25628856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas.
    Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S
    Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.
    Stacchiotti S; Dagrada GP; Sanfilippo R; Negri T; Vittimberga I; Ferrari S; Grosso F; Apice G; Tricomi M; Colombo C; Gronchi A; Dei Tos AP; Pilotti S; Casali PG
    Clin Sarcoma Res; 2013 Dec; 3(1):16. PubMed ID: 24345066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study.
    Siehl JM; Thiel E; Schmittel A; Hütter G; Deckert PM; Szelényi H; Keilholz U
    Cancer; 2005 Aug; 104(3):611-7. PubMed ID: 15968689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network.
    Stacchiotti S; Palassini E; Sanfilippo R; Vincenzi B; Arena MG; Bochicchio AM; De Rosa P; Nuzzo A; Turano S; Morosi C; Dei Tos AP; Pilotti S; Casali PG
    Ann Oncol; 2012 Feb; 23(2):501-8. PubMed ID: 21464156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database.
    Stacchiotti S; Provenzano S; Dagrada G; Negri T; Brich S; Basso U; Brunello A; Grosso F; Galli L; Palassini E; Libertini M; Colia V; Gronchi A; Dei Tos AP; Crippa F; Morosi C; Pilotti S; Casali PG
    Ann Surg Oncol; 2016 Sep; 23(9):2735-44. PubMed ID: 27334221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study.
    García Del Muro X; Maurel J; Martínez Trufero J; Lavernia J; López Pousa A; de Las Peñas R; Cubedo R; Berros JP; Casado Herráez A; de Juan A; Martín Broto J
    Invest New Drugs; 2018 Jun; 36(3):468-475. PubMed ID: 29527631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Continuous-infusion high dose ifosfamide as salvage treatment for pre-treated soft tissue sarcoma].
    Chen LK; Xu GC; Teng XY; Liang Y; Liu JL; Zhou XM
    Ai Zheng; 2002 Aug; 21(8):903-6. PubMed ID: 12478904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
    Moon YW; Sohn JH; Choi HJ; Chang H; Park BW; Kim SI; Park S; Koo JS; Kim YT; Roh JK; Chung HC; Kim JH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):425-31. PubMed ID: 20012956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
    Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
    Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of palliative chemotherapy in advanced epithelioid sarcoma.
    Jones RL; Constantinidou A; Olmos D; Thway K; Fisher C; Al-Muderis O; Scurr M; Judson IR
    Am J Clin Oncol; 2012 Aug; 35(4):351-7. PubMed ID: 21422990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel-ifosfamide for anthracycline-resistant advanced breast cancer.
    Kellokumpu-Lehtinen P; Lantto A; Kokko R; Elomaa L; Järvenpää R; Lehtinen R; Blomqvist C
    Int J Clin Pharmacol Res; 2002; 22(2):47-53. PubMed ID: 12503775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel-ifosfamide combination in patients with HER2-non-overexpressing advanced breast cancer failing prior anthracyclines.
    Kosmas C; Tsavaris N; Malamos N; Tsakonas G; Gassiamis A; Polyzos A; Mylonakis N; Karabelis A
    Invest New Drugs; 2007 Oct; 25(5):463-70. PubMed ID: 17370037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
    Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas.
    De Pas T; Curigliano G; Masci G; Catania C; Comandone A; Boni C; Tucci A; Pagani O; Marrocco E; de Braud F;
    Ann Oncol; 2002 Jan; 13(1):161-6. PubMed ID: 11863099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.